NLRP3炎癥小體與炎癥性腸病的關(guān)系及針灸調(diào)節(jié)作用研究進(jìn)展

吳麗潔,張霽,張丹,楊延婷,楊玲,智方圓,吳凌翔,謝晨,馬曉芃,

?

NLRP3炎癥小體與炎癥性腸病的關(guān)系及針灸調(diào)節(jié)作用研究進(jìn)展

吳麗潔1,張霽1,張丹2,楊延婷1,楊玲2,智方圓1,吳凌翔2,謝晨2,馬曉芃1,2

(1.上海中醫(yī)藥大學(xué),上海 201203;2.上海市針灸經(jīng)絡(luò)研究所,上海 200030)

炎癥性腸病(inflammatory bowel disease, IBD)是一組慢性非特異性腸道炎癥性疾病,包括潰瘍性結(jié)腸炎(UC)和克羅恩病(CD)。炎癥小體作為一種大分子復(fù)合蛋白,在炎癥發(fā)生發(fā)展與機(jī)體固有免疫中發(fā)揮了重要作用。其中NLRP3在IBD的發(fā)生發(fā)展與維持腸道穩(wěn)態(tài)的作用機(jī)制中起到了雙向調(diào)節(jié)的作用。該文綜述了NLRP3炎性小體在IBD中的研究進(jìn)展以及針灸對(duì)其的調(diào)節(jié)作用及可能機(jī)制,以期為針灸治療炎癥性腸病的臨床和機(jī)制研究提供新思路。

炎癥性腸病;針灸療法;炎癥小體;NLRP3

炎癥性腸病(inflammatory bowel disease, IBD)是一組影響胃腸道功能的慢性炎癥性疾病,主要包括克羅恩病(CD)和潰瘍性結(jié)腸炎(UC)[1]。其發(fā)病機(jī)制尚未完全明確,可能與腸道上皮屏障功能的改變、腸道微生物失調(diào)、腸道先天免疫和飲食等因素相關(guān)[2]。NLRP3作為炎癥小體的其中一個(gè)亞型,是目前研究最多也是最具特點(diǎn)的一員,對(duì)炎癥性腸病的調(diào)控具有雙向調(diào)節(jié)作用[3]。大量的臨床實(shí)踐已證明,針灸治療炎癥性腸病療效確切[4-27],機(jī)制研究也逐步深入。探討NLRP3在IBD中的分子調(diào)節(jié)機(jī)制以及針灸干預(yù)作用,為針灸治療IBD提供可靠的科學(xué)依據(jù)具有重要意義。

1 NLRP3炎癥小體的組成

NLRP3炎癥小體是一種存在于細(xì)胞質(zhì)中的蛋白復(fù)合物,由NLRP3、凋亡相關(guān)斑點(diǎn)樣蛋白(ASC)以及半胱天冬肽酶-1(caspase-1)前體蛋白結(jié)合而成。NLRP3由C端亮氨酸重復(fù)序列(LRR)和核苷酸寡聚化結(jié)構(gòu)域(NACTH)以及N端效應(yīng)結(jié)構(gòu)域(PYD)組成[28],其中PYD連接ASC的PYD結(jié)構(gòu)域后,ASC的C端CARD(caspase recruitment domain)結(jié)構(gòu)域招募caspase-1前體,進(jìn)而激活caspase-1,實(shí)現(xiàn)炎癥小體NLRP3的裝配[29]。靜息狀態(tài)時(shí),NLRP3處于無(wú)活性狀態(tài),只有被激活后才能轉(zhuǎn)化為炎癥小體發(fā)揮作用,具體的激活物分為病原相關(guān)分子模式(PAMPs)和損傷相關(guān)分子模式(DAMPs),其中PAMPS主要包括金黃色葡萄球菌、B組鏈球菌、李斯特氏菌、病毒[30-33]等;DAMPS主要包括尿酸或膽固醇結(jié)晶、b淀粉狀蛋白、三磷酸腺苷(ATP)等[34-36]。當(dāng)PAMPs或DAMPs被Toll樣受體(第一信號(hào))識(shí)別后,激活核轉(zhuǎn)錄因子NF-kB,啟動(dòng)NLRP3、pro-IL-1b和pro-IL-18等的轉(zhuǎn)錄過(guò)程,進(jìn)而上調(diào)炎癥小體的表達(dá)水平。第二信號(hào)(ATP,某些細(xì)菌毒素或顆粒物質(zhì))介導(dǎo)NLRP3的寡聚化,將NLRP3、ASC和caspase-1前體蛋白裝配成復(fù)合物,引起caspase-1的活化以及IL-1b和IL-18的分泌[37-38]。

2 NLRP3炎癥小體的激活途徑

目前,NLRP3炎癥小體主要存在4種激活路徑。①細(xì)胞外的ATP(三磷酸腺苷)充當(dāng)NLRP3受體激動(dòng)劑,通過(guò)結(jié)合表面受體P2X7,使離子通道打開(kāi)。同時(shí),細(xì)菌毒素使細(xì)胞膜形成空隙,從而誘導(dǎo)K﹢外流,從而導(dǎo)致NLRP3炎癥小體的組裝和激活?？梢哉J(rèn)為,K﹢外流是NLRP3炎癥小體的主要催化劑,而細(xì)胞外ATP和成孔毒素是炎癥因子分泌的主要誘因[39]。②在PAMPs和DAMPs影響下,損傷的線粒體激發(fā)活性氧(ROS)、線粒體DNA和心磷脂的產(chǎn)生,作為激活NLRP3炎癥小體的關(guān)鍵信號(hào)導(dǎo)致NLRP3裝配和激活[40-41]。③結(jié)晶或顆粒結(jié)構(gòu)(如二氧化硅、石棉、淀粉樣蛋白b和明礬等)刺激吞噬細(xì)胞內(nèi)環(huán)境的穩(wěn)定,引起溶酶體破裂,組織蛋白酶B釋放到細(xì)胞質(zhì)中,直接激活炎性小體[42]。④Ca2﹢通量和Ca2﹢依賴性信號(hào)觸發(fā)NLRP3炎癥小體組裝[43-44]。

最近的研究表明,NIMA相關(guān)激酶(NEK)家族的成員NEK7直接與NLRP3的LRR結(jié)構(gòu)域結(jié)合,在K﹢外排和ROS產(chǎn)生作用下,完成炎癥小體的組裝與激活[45]。Wang W等[46]發(fā)現(xiàn)EV71(腸道病毒71)3D蛋白作為RNA依賴性RNA聚合酶,通過(guò)直接結(jié)合NLRP3刺激NLRP3炎性細(xì)胞的活化。除此之外,自噬功能障礙、線粒體鈣離子超載引起的功能失調(diào)、TXNIP的活化、PYD結(jié)構(gòu)域的磷酸化、高爾基體介導(dǎo)的蛋白激酶D信號(hào)傳導(dǎo)、氯離子等因素也可以激活NLRP3炎癥小體[47-51]。NLRP3炎癥小體組裝與激活途徑如圖1所示。

然而NLRP3炎癥小體的不適當(dāng)激活會(huì)破壞先天性免疫應(yīng)答在人體的防御作用,研究表明,胰腺癌、動(dòng)脈硬化、糖尿病、慢性肝病、帕金森等自身免疫相關(guān)性疾病都與其相關(guān)[52-56]。

3 NLRP3的負(fù)調(diào)控途徑

近幾年發(fā)現(xiàn),NLRP3的激活可以被自噬等多種調(diào)控途徑所抑制。自噬作為一種自我降解過(guò)程,在某些條件下,可以選擇性去除特定的蛋白質(zhì)和受損的細(xì)胞器(如線粒體)[57],從而維持細(xì)胞代謝平衡,實(shí)現(xiàn)內(nèi)環(huán)境穩(wěn)態(tài)。自噬由4個(gè)連續(xù)步驟組成,自噬體的形成,自噬膜的伸長(zhǎng)和閉合,自噬體和溶酶體之間的融合以及降解,這種復(fù)雜過(guò)程在哺乳動(dòng)物中至少由18個(gè)自噬相關(guān)基因(Atg基因)介導(dǎo)[58]。最近的研究已經(jīng)確定了自噬相關(guān)基因在NLRP3炎癥細(xì)胞活化中的關(guān)鍵作用,如Saitoh T等[59]發(fā)現(xiàn)Atg16L1可以通過(guò)促進(jìn)自噬體P62的降解來(lái)抑制IL-1b的分泌;van der Burgh R等[60]發(fā)現(xiàn)Atg7缺陷導(dǎo)致線粒體受損,NLRP3炎癥體活化,與自噬可以通過(guò)清除損傷的線粒體直接抑制NLRP3炎癥體激活的結(jié)論一致[61]。有研究[61-62]發(fā)現(xiàn)3MA(PI3K抑制劑)抑制自噬增加了mtROS的產(chǎn)生,導(dǎo)致在沒(méi)有炎性體刺激的情況下,NLRP3依賴性IL-1b分泌;在干預(yù)結(jié)核分枝桿菌感染的細(xì)胞時(shí),3MA阻斷自噬體形成導(dǎo)致IL-1b分泌增加。Spalinger MR等[63]發(fā)現(xiàn)PTPN22(蛋白酪氨酸磷酸酶,非受體型22)的喪失通過(guò)自噬途徑,增強(qiáng)的NLRP3磷酸化水平抑制NLRP3炎癥體的激活。除此之外,作為Fork框架轉(zhuǎn)錄因子家族的成員,Foxo3a在營(yíng)養(yǎng)缺乏條件下參與自噬形成。研究證實(shí),Foxo3a在細(xì)胞核中被抑制使自噬功能受損,NLRP3炎癥細(xì)胞在KCs中被激活;Foxo3a的過(guò)表達(dá)恢復(fù)自噬通量,并通過(guò)促進(jìn)Bim的轉(zhuǎn)錄來(lái)減弱NLRP3炎癥細(xì)胞的活化[64]。

注:紅色箭頭與字體為第一信號(hào),黑色為第二信號(hào),①②③④為主要激活途徑

除自噬外,泛素相關(guān)蛋白可以負(fù)調(diào)控NLRP3的激活。E3泛素連接酶TRIM31(三分體基序蛋白31)被認(rèn)為是NLRP3炎癥反應(yīng)抑制因子,它可以直接結(jié)合NLRP3,促進(jìn)NLRP3的K48連鎖聚泛素化和蛋白酶體降解,同時(shí),TRIM31缺乏可以減輕DSS誘導(dǎo)的結(jié)腸炎[65]。另外,TRIM30通過(guò)抑制細(xì)胞內(nèi)ROS的產(chǎn)生,從而抑制NLRP3炎癥小體激活[66]。

此外,NO與CO以及Nrf2(核轉(zhuǎn)錄因子E2相關(guān)因子2)通過(guò)抑制線粒體中ROS的產(chǎn)生,線粒體膜電位,和線粒體DNA在巨噬細(xì)胞中的胞內(nèi)易位,維持線粒體穩(wěn)定來(lái)抑制NLRP3的表達(dá),ASC的裝配和IL-1b分泌達(dá)到負(fù)調(diào)控的作用[67-69]。研究發(fā)現(xiàn),NLRP3炎癥體激活物觸發(fā)Src同源2域包含蛋白酪氨酸磷酸酶-2(SHP2)易位到線粒體,與腺嘌呤核苷酸t(yī)ranslocase 1(ANT1)相互作用和去磷酸化抑制線粒體膜電位以及線粒體DNA和活性氧的釋放,從而防止NLRP3炎癥小體的過(guò)度激活[70]。

4 NLRP3炎癥小體與IBD的關(guān)系

近幾年的研究發(fā)現(xiàn),NLRP3在IBD的發(fā)病與炎癥中具有促進(jìn)炎癥與維持腸道穩(wěn)態(tài)的雙重作用[3]。

4.1 NLRP3在IBD病理學(xué)中的促炎作用

研究顯示,在CD患者和患有急性或慢性結(jié)腸炎小鼠的結(jié)腸組織中存在NLRP3的高表達(dá)[33,71-73]。與NLRP3相關(guān)NLRs家族中的NOD1和NOD2存在于細(xì)胞質(zhì)中,它們分別識(shí)別細(xì)菌肽聚糖、胞壁酰二肽,Paneth細(xì)胞、上皮細(xì)胞和抗原呈遞細(xì)胞中的轉(zhuǎn)錄因子NF-kB和AP-1被活化,導(dǎo)致促炎因子IL-b的釋放[74]。DE la Fuente M等[75]發(fā)現(xiàn)從IBD患者分離的大腸桿菌菌株可以通過(guò)NLRP3炎癥小體誘導(dǎo)小鼠巨噬細(xì)胞的IL-1b分泌。Liu W等[76]使用NLRP3依賴的pro-caspase-1、IL-1b和IL-18的抑制劑Fc11a-2來(lái)治療模型小鼠,急性結(jié)腸炎的癥狀得到減輕。Bauer C等[77]發(fā)現(xiàn),與正常小鼠對(duì)比,NLRP3-/-小鼠在DSS造模的情況下,結(jié)腸炎的嚴(yán)重程度明顯下降。以上這些研究均提示,NLRP3對(duì)結(jié)腸炎的發(fā)生發(fā)展具有促進(jìn)作用,且可以作為開(kāi)發(fā)IBD患者的新型治療劑的潛在靶標(biāo)。

4.2 NLRP3維持腸道內(nèi)穩(wěn)態(tài)作用

NLRP3在調(diào)節(jié)腸內(nèi)穩(wěn)態(tài)中起著關(guān)鍵作用,維持腸道上皮屏障完整性并降低實(shí)驗(yàn)性結(jié)腸炎期間的死亡率,并影響腸道內(nèi)生物群的組成[48,78-80]。研究發(fā)現(xiàn)攜帶NLRP3 R258W突變的CAPS模型小鼠通過(guò)調(diào)節(jié)性T細(xì)胞(Treg細(xì)胞)誘導(dǎo)IL-1b的分泌增加,促進(jìn)局部抗微生物肽促進(jìn)微生物群的重建,從而維持腸道穩(wěn)態(tài)[81]。有學(xué)者[78-79,82]發(fā)現(xiàn)和NLRP3-/-、ASC-/-和caspase-1-/-小鼠對(duì)葡聚糖硫酸鈉(DSS)和2,4,6-三硝基苯磺酸(TNBS)誘導(dǎo)的結(jié)腸炎更易感染,小鼠腸道上皮細(xì)胞增殖缺陷,上皮屏障功能減弱,細(xì)菌的透過(guò)率升高,從而使易感性增加。除此之外,NLLRP3-/-小鼠在NO合成酶(iNOS)活性增加的誘導(dǎo)情況下,NO水平升高,IL-10和TGF-b表達(dá)降低,從而表明NLRP3可以在腸炎中下調(diào)炎癥反應(yīng),在腸內(nèi)穩(wěn)態(tài)中起關(guān)鍵作用[79]。在惡唑酮(OXA)誘導(dǎo)的結(jié)腸炎WT小鼠模型中,外源性IL-1b、IL-18可通過(guò)調(diào)節(jié)Th2細(xì)胞因子的表達(dá),降低結(jié)腸炎的嚴(yán)重性。而NLRP3-/-小鼠結(jié)腸炎的嚴(yán)重性與Th2細(xì)胞因子的表達(dá)呈正相關(guān)。這提示NLRP3衍生的IL-1b、IL-18可以通過(guò)不同的機(jī)制抑制Th2細(xì)胞因子產(chǎn)生,減輕腸道損傷[83]。研究還發(fā)現(xiàn)NLRP3炎癥小體可以調(diào)節(jié)上皮細(xì)胞的衍生物IL-18的分泌,來(lái)維持腸道穩(wěn)態(tài)[84]。以上研究均提示NLRP3炎癥小體對(duì)實(shí)驗(yàn)性結(jié)腸炎有保護(hù)作用。

隨著研究的深入,雖然研究者對(duì)NLRP3炎癥小體有了較多的認(rèn)識(shí),但其在IBD中的作用機(jī)制尚不明確,對(duì)于NLRP3炎癥小體表達(dá)水平對(duì)結(jié)腸炎的影響仍然存在爭(zhēng)議。特別是在NLRP3-/-小鼠結(jié)腸炎模型中的結(jié)果差異,可能與誘導(dǎo)結(jié)腸炎的方案、實(shí)驗(yàn)條件、遺傳背景和所使用的動(dòng)物的性別以及不同小鼠之間不同微生物群落等差異相關(guān)[85]。所以如要確定NLRP3炎癥小體在穩(wěn)定狀態(tài)條件下和在IBD中發(fā)揮的作用需要做進(jìn)一步的研究。

5 針灸對(duì)炎癥性腸病NLRP3炎癥小體的作用與展望

目前,針灸對(duì)炎癥性腸病NLRP3炎癥小體是否有調(diào)節(jié)作用尚未見(jiàn)有報(bào)道,但業(yè)已證實(shí)針灸對(duì)NLRP3信號(hào)通路的激活因素、下游炎癥因子以及負(fù)調(diào)控的相關(guān)因素,有一定的調(diào)節(jié)作用,提示調(diào)節(jié)NLRP3炎癥小體及相關(guān)信號(hào)通路可能是針灸治療IBD的重要效應(yīng)機(jī)制。

NF-kB與NLRP3炎癥小體的組裝與激活相關(guān),研究發(fā)現(xiàn)針灸對(duì)IBD核轉(zhuǎn)錄因子NF-kB及下游炎癥因子有調(diào)節(jié)作用。

在克羅恩病中,研究發(fā)現(xiàn)電針刺激足三里、曲池穴能夠減輕TNBS誘導(dǎo)的結(jié)腸病變,與其下調(diào)IL-1b的表達(dá),以及抑制p-IkBa和NF-kB p65等蛋白表達(dá)水平相關(guān)[86];艾灸天樞、氣海穴,能下調(diào)克羅恩病大鼠結(jié)腸NF-kB p65、TNF-a、IL-1b的表達(dá),提示艾灸可能通過(guò)抑制克羅恩病大鼠結(jié)腸NF-kB p65的表達(dá),進(jìn)而減少其下游炎癥因子TNF-a、IL-1b的表達(dá),從而減輕腸道炎癥,改善結(jié)腸組織形態(tài)結(jié)構(gòu),發(fā)揮治療作用[87]。在潰瘍性結(jié)腸炎中,研究發(fā)現(xiàn),電針上巨虛能調(diào)節(jié)潰瘍性結(jié)腸炎IL-1b的異常表達(dá),改善結(jié)腸黏膜損傷[88];大鼠潰瘍性結(jié)腸炎的發(fā)生涉及多種基因的表達(dá)異常,隔藥灸可通過(guò)調(diào)節(jié)IL-1b等諸多基因表達(dá)起到治療作用[89]。艾灸可通過(guò)抑制結(jié)腸組織NF-kB p65轉(zhuǎn)錄而下調(diào)TLR-9表達(dá),從而修復(fù)UC大鼠受損黏膜上皮,抑制血清中IL-8含量,提高血清中IL-10含量,且灸量越大效果越明顯[90]。還有研究發(fā)現(xiàn)調(diào)控TLR/MyD88/NF-kB信號(hào)轉(zhuǎn)導(dǎo)通路中MyD88、TRAF6的表達(dá)是隔藥灸調(diào)節(jié)潰瘍性結(jié)腸炎結(jié)腸黏膜局部過(guò)激免疫炎癥反應(yīng)的作用途徑之一[91]。

除此之外,針灸對(duì)NLRP3負(fù)調(diào)控途徑的相關(guān)因素也有一定的作用。有研究發(fā)現(xiàn),在金黃色葡萄球菌引起的巨噬細(xì)胞感染中,溫和灸可以下調(diào)IL-1b、iNOS以及caspase-1的表達(dá),減輕炎癥;除此之外還證實(shí)了,溫和灸是通過(guò)下調(diào)自噬mTOR通路中Akt的磷酸化水平來(lái)起到作用的[92]。

綜上所述,針灸對(duì)NLRP3炎癥小體下游炎癥因子、調(diào)控途徑均有一定的調(diào)節(jié)作用。NLRP3炎癥小體作為系列炎癥反應(yīng)的核心,可能是針灸防治炎癥性腸病新的重要靶點(diǎn)。探討艾灸調(diào)節(jié)炎癥小體及其相關(guān)信號(hào)通路治療炎癥性腸病的效應(yīng)機(jī)制,對(duì)于炎癥性腸病的防治至關(guān)重要。以NLRP3炎癥小體為介入點(diǎn),觀察針灸對(duì)炎癥性腸病NLRP3炎癥小體及上下游通路信號(hào)分子的調(diào)節(jié)作用,闡釋針灸對(duì)NLRP3炎癥小體調(diào)控的分子機(jī)制,有助于進(jìn)一步闡明針灸防治炎癥性腸病的作用機(jī)制,為臨床炎癥性腸病的針灸治療提供科學(xué)證據(jù)。

[1] Gersemann M, Wehkamp J, Stange EF. Innate immune dysfunction in inflammatory bowel disease[J]., 2012,271(5):421-428.

[2] de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art[J]., 2016,13(1):13-27.

[3] Gorfu G, Cirelli KM, Melo MB,. Dual role for inflammasome sensors NLRP1 and NLRP3 in murine resistance to Toxoplasma gondii[J]., 2014,5(1): e01117-e01123.

[4] 包春輝,吳璐一,吳煥淦,等.針灸治療活動(dòng)期克羅恩病:隨機(jī)對(duì)照研究[J].中國(guó)針灸,2016,36(7):683-688.

[5] 陳俊玲,趙洪霄.隔藥餅灸治療慢性潰瘍性結(jié)腸炎50例療效觀察[J].新疆中醫(yī)藥,2017,35(1):13-15.

[6] 陳淑君.穴位埋線治療潰瘍性結(jié)腸炎的療效及對(duì)抗中性粒細(xì)胞胞漿抗體的影響[J].中醫(yī)臨床研究,2015,7 (3):78-80.

[7] 高培彥.中醫(yī)針灸對(duì)潰瘍性結(jié)腸炎的臨床療效觀察[J].大家健康(學(xué)術(shù)版),2015,9(9):21.

[8] 郭保君,陸鵬,張鐳瀟,等.針灸健脾補(bǔ)腎法治療潰瘍性結(jié)腸炎療效觀察[J].四川中醫(yī),2016,34(5):182-185.

[9] 韓國(guó)勇.溫針灸治療脾腎陽(yáng)虛型慢性潰瘍性結(jié)腸炎臨床研究[J].亞太傳統(tǒng)醫(yī)藥,2015,11(22):102-103.

[10] 何邦廣,吳海標(biāo),錢(qián)火輝.溫針灸治療脾虛型潰瘍性結(jié)腸炎臨床觀察[J].吉林中醫(yī)藥,2009,29(5):410-411.

[11] 賀君,廖穆熙,孟珍珍.針刺聯(lián)合臍環(huán)穴隔姜灸治療脾腎陽(yáng)虛型潰瘍性結(jié)腸炎臨床療效及對(duì)相關(guān)炎性因子的影響[J].廣州中醫(yī)藥大學(xué)學(xué)報(bào),2015,32(4):687-689, 693.

[12] 黃艷平.艾灸在潰瘍性結(jié)腸炎臨床治療中應(yīng)用觀察[J].中國(guó)現(xiàn)代藥物應(yīng)用,2015,9(21):259-260.

[13] 蔣海燕.中醫(yī)針灸治療慢性潰瘍性結(jié)腸炎療效觀察[J].中醫(yī)臨床研究,2015,7(30):109-110.

[14] 劉小紅.針灸治療慢性潰瘍性結(jié)腸炎的臨床療效[J].光明中醫(yī),2016,31(21):3173-3174.

[15] 陸嫄,包春輝,吳璐一,等.艾灸治療潰瘍性結(jié)腸炎的臨床與實(shí)驗(yàn)研究進(jìn)展[J].中華中醫(yī)藥學(xué)刊,2013,31 (6):1261-1264.

[16] 欒炳玉.針灸治療潰瘍性結(jié)腸炎療效觀察[J].亞太傳統(tǒng)醫(yī)藥,2016,12(20):90-91.

[17] 呂偉.重灸神闕穴治療脾腎陽(yáng)虛型潰瘍性結(jié)腸炎[J].內(nèi)蒙古中醫(yī)藥,2015,34(9):46.

[18] 米嬿.針灸治療慢性潰瘍性結(jié)腸炎的療效觀察[J].內(nèi)蒙古中醫(yī)藥,2015,34(3):50-51.

[19] 歐亞,吾爾納,徐君超.溫針灸治療脾虛型潰瘍性結(jié)腸炎35例臨床觀察[J].中國(guó)民族民間醫(yī)藥,2014,15 (24):55,57.

[20] 宋宸宇.艾灸治療脾胃虛寒型潰瘍性結(jié)腸炎60例臨床分析[J].亞太傳統(tǒng)醫(yī)藥,2014,10(21):53-54.

[21] 宋宸宇,劉麗爽.艾灸治療脾腎陽(yáng)虛型潰瘍性結(jié)腸炎30例臨床體會(huì)[J].亞太傳統(tǒng)醫(yī)藥,2015,11(18):98- 99.

[22] 王允娜,牛崇信.溫通針?lè)ㄖ委熎⒛I陽(yáng)虛型潰瘍性結(jié)腸炎臨床療效及對(duì)相關(guān)炎性因子的影響[J].西部中醫(yī)藥, 2017,30(5):114-116.

[23] 王增.探討中醫(yī)針灸治療慢性潰瘍性結(jié)腸炎療效[J].光明中醫(yī),2016,31(8):1142-1144.

[24] 肖再軍.穴位艾灸治療脾腎陽(yáng)虛型潰瘍性結(jié)腸炎102例臨床觀察[J].北方藥學(xué),2014,11(3):98-99.

[25] 許力榮.中醫(yī)針灸治療慢性潰瘍性結(jié)腸炎療效觀察[J].世界最新醫(yī)學(xué)信息文摘,2016,16(49):206.

[26] 楊金鎖.中醫(yī)針灸治療慢性潰瘍性結(jié)腸炎的方法及效果評(píng)價(jià)[J].中醫(yī)臨床研究,2016,8(26):27-28.

[27] 楊周雨,賁定嚴(yán),易展,等.隔藥餅灸治療脾虛濕蘊(yùn)證輕中度潰瘍性結(jié)腸炎臨床研究[J].中國(guó)中醫(yī)藥信息雜志, 2017,24(4):32-35.

[28] Garib FY, Rizopulu AP, Kuchmiy AA,. Inactivation of Inflammasomes by Pathogens Regulates Inflamma- tion[J].(), 2016,81(11):1326-1339.

[29] Bryan NB1, Dorfleutner A, Rojanasakul Y,. Activation of inflammasomes requires intracellular redistribution of the apoptotic speck-like protein containing a caspase recruitment domain[J]., 2009,182(5):3173-3182.

[30] Mariathasan S, Weiss DS, Newton K,. Cryopyrin activates the inflammasome in response to toxins and ATP[J]., 2006,440(7081):228-232.

[31] Costa A, Gupta R, Signorino G,. Activation of the NLRP3 inflammasome by group B streptococci[J]., 2012,188(4):1953-1960.

[32] Duncan JA, Gao X, Huang MT,. Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC- containing inflammasome[J]., 2009,182(10): 6460-6469.

[33] Allen IC, Scull MA, Moore CB,. The NLRP3 inflammasome mediates in vivo innate immunity to

influenza A virus through recognition of viral RNA[J]., 2009,30(4):556-565.

[34] Vanaja SK, Rathinam VA, Fitzgerald KA. Mechanisms of inflammasome activation: recent advances and novel insights[J]., 2015,25(5):308-315.

[35] Dostert C, Pétrilli V, Van Bruggen R,. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica[J]., 2008,320(5876):674- 677.

[36] Abderrazak A, Syrovets T, Couchie D,. NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases[J]., 2015,4:296-307.

[37] Franchi L, Mu?oz-Planillo R, Nú?ez G. Sensing and reacting to microbes through the inflammasomes[J]., 2012,13(4):325-332.

[38] Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes[J]., 2014,157(5):1013-1022.

[39] Karmakar M, Katsnelson MA, Dubyak GR,. Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1bsecretion in response to ATP[J]., 2016,7:10555.

[40] Crane DD, Bauler TJ, Wehrly TD,. Mitochondrial ROS potentiates indirect activation of the AIM2 inflammasome[J]., 2014,5:438.

[41] Park S, Won JH, Hwang I,. Defective mitochondrial fission augments NLRP3 inflammasome activation[J]., 2015,5:15489.

[42] Lima H Jr, Jacobson LS, Goldberg MF,. Role of lysosome rupture in controlling Nlrp3 signaling and necrotic cell death[J]., 2013,12 (12):1868-1878.

[43] Lee GS, Subramanian N, Kim AI,. The calcium- sensing receptor regulates the NLRP3 inflammasome through Ca2﹢and cAMP[J]., 2012,492 (7427):123-127.

[44] Murakami T, Ockinger J, Yu J,. Critical role for calcium mobilization in activation of the NLRP3 inflammasome[J]., 2012,109 (28):11282-11287.

[45] Shi H, Wang Y, Li X,. NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component[J]., 2016,17(3):250-258.

[46] Wang W, Xiao F, Wan P,. EV71 3D protein binds with NLRP3 and enhances the assembly of inflammasome complex[J]., 2017,13(1): e1006123.

[47] Jabir MS, Hopkins L, Ritchie ND,. Mitochondrial damage contributes to Pseudomonas aeruginosa activation of the inflammasome and is downregulated by autophagy[J]., 2015,11(1):166-182.

[48] Miao H, Ou J, Ma Y,. Macrophage CGI-58 deficiency activates ROS-inflammasome pathway to promote insulin resistance in mice[J]., 2014,7 (1):223-235.

[49] Stutz A, Kolbe CC, Stahl R,. NLRP3 inflammasome assembly is regulated by phosphorylation of the pyrin domain[J]., 2017,214(6):1725-1736.

[50] Zhang Z, Meszaros G, He WT,. Protein kinase D at the Golgi controls NLRP3 inflammasome activation[J]., 2017,214(9):2671-2693.

[51] Tang T, Lang X, Xu C,. CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation[J]., 2017, 8(1):202.

[52] Daley D, Mani VR, Mohan N,. NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma[J]., 2017, 214(6):1711-1724.

[53] Sharma A, Tate M, Mathew G,. Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications[J]., 2018,9:114.

[54] Wu X, Dong L, Lin X,. Relevance of the NLRP3 Inflammasome in the Pathogenesis of Chronic Liver Disease[J]., 2017,8:1728.

[55] Sarkar S, Malovic E, Harishchandra DS,. Mitochon- drial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson’s disease[J]., 2017,3:30.

[56] Wang R, Wang Y, Mu N,. Activation of NLRP3 inflammasomes contributes to hyperhomocysteinemia- aggravated inflammation and atherosclerosis in apoE- deficient mice[J]., 2017,97(8):922-934.

[57] Saito T, Sadoshima J. Molecular mechanisms of mitoch- ondrial autophagy/mitophagy in the heart[J]., 2015,116(8):1477-1490.

[58] Mizushima N, Levine B. Autophagy in mammalian development and differentiation[J]., 2010,12(9):823-830.

[59] Saitoh T, Fujita N, Jang MH,. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production[J]., 2008,456(7219):264-268.

[60] van der Burgh R, Nijhuis L, Pervolaraki K,. Defects in mitochondrial clearance predispose human monocytes to interleukin-1bhypersecretion[J]., 2014, 289(8):5000-5012.

[61] Alfonso-Loeches S, Ure?a-Peralta JR, Morillo-Bargues MJ,. Role of mitochondria ROS generation in ethanol-induced NLRP3 inflammasome activation and cell death in astroglial cells[J]., 2014, 8:216.

[62] Harris J, Hartman M, Roche C,. Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation[J]., 2011,286(11):9587- 9597.

[63] Spalinger MR, Lang S, Gottier C,. PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy- dependent manner[J]., 2017,13 (9):1590-1601.

[64] Liu Y, Zhang W, Wu X,. Foxo3a-dependent Bim transcription protects mice from a high fat diet via inhibition of activation of the NLRP3 inflammasome by facilitating autophagy flux in Kupffer cells[J]., 2017,8(21):34258-34267.

[65] Song H, Liu B, Huai W,. The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3[J]., 2016,7:13727.

[66] Hu Y, Mao K, Zeng Y,. Tripartite-motif protein 30 negatively regulates NLRP3 inflammasome activation by modulating reactive oxygen species production[J]., 2010,185(12):7699-7705.

[67] Jung SS, Moon JS, Xu JF,. Carbon monoxide negatively regulates NLRP3 inflammasome activation in macrophages[J]., 2015,308(10):L1058-L1067.

[68] Liu X, Zhang X, Ding Y,. Nuclear factor E2-related factor-2 negatively regulates NLRP3 inflammasome activity by inhibiting reactive oxygen species-induced NLRP3 priming[J].al, 2017,26(1): 28-43.

[69] Mao K, Chen S, Chen M,. Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock[J]., 2013,23(2): 201-212.

[70] Guo W, Liu W, Chen Z,. Tyrosine phosphatase SHP2 negatively regulates NLRP3 inflammasome activation via ANT1-dependent mitochondrial homeostasis[J]., 2017,8(1):2168.

[71] Zhang J, Fu S, Sun S,. Inflammasome activation has an important role in the development of spontaneous colitis[J]., 2014,7(5):1139-1150.

[72] Bauer C, Duewell P, Lehr HA,. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors[J]., 2012,30(Suppl 1):82-90.

[73] Zhang Z, Shen P, Lu X,.andstudy on the efficacy of terpinen-4-ol in dextran sulfate sodium- induced mice experimental colitis[J]., 2017,8:558.

[74] Sahoo BR, Swain B, Dikhit MR,. Activation of nucleotide-binding oligomerization domain 1 (NOD1) receptor signaling in Labeo rohita by iE-DAP and identification of ligand-binding key motifs in NOD1 by molecular modeling and docking[J]., 2013,170(6):1282-1309.

[75] De la Fuente M, Franchi L, Araya D,. Escherichia coli isolates from inflammatory bowel diseases patients survive in macrophages and activate NLRP3 inflammasome[J]., 2014,304(3-4): 384-392.

[76] Liu W, Guo W, Wu J,. A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome[J]., 2013,85(10):1504-1512.

[77] Bauer C, Duewell P, Mayer C,. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome[J]., 2010,59 (9):1192-1199.

[78] Hirota SA, Ng J, Lueng A,. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis[J]., 2011,17 (6):1359-1372.

[79] Zaki MH, Boyd KL, Vogel P,. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis[J]., 2010,32(3):379-391.

[80] Dupaul-Chicoine J, Yeretssian G, Doiron K,. Control of intestinal homeostasis, colitis, and colitis-associatedcolorectal cancer by the inflammatory caspases[J]., 2010,32(3):367-378.

[81] Yao X, Zhang C, Xing Y,. Remodelling of the gut microbiota by hyperactive NLRP3 induces regulatory T cells to maintain homeostasis[J]., 2017,8 (1):1896.

[82] Allen IC, TeKippe EM, Woodford RM,. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer[J]., 2010,207(5):1045-1056.

[83] Itani S, Watanabe T, Nadatani Y,. NLRP3 inflammasome has a protective effect against oxazolone- induced colitis: a possible role in ulcerative colitis[J]., 2016,6:39075.

[84] Liu JJ, Davis EM, Wine E,. Epithelial cell extrusion leads to breaches in the intestinal epithelium[J]., 2013,19(5):912-921.

[85] Elinav E, Thaiss CA, Flavell RA. Analysis of microbiota alterations in inflammasome-deficient mice[J]., 2013,1040:185-194.

[86] 施麗薇,顧晗,劉明江,等.針刺對(duì)潰瘍性結(jié)腸炎大鼠結(jié)腸炎性細(xì)胞因子及細(xì)胞凋亡的影響[J].針刺研究, 2017,42(1):56-61.

[87] 魏凱,張丹,竇傳字,等.艾灸對(duì)克羅恩病大鼠結(jié)腸NF-kB p65及TNF-a、IL-1b調(diào)節(jié)作用的研究[J].世界中醫(yī)藥,2013,8(8):862-866,870.

[88] 易細(xì)芹,張泓,凌希,等.電針對(duì)潰瘍性結(jié)腸炎大鼠結(jié)腸IL-1b及nAchRa7mRNA的影響[J].上海針灸雜志,2016, 35(10):1251-1255.

[89] 吳煥淦,劉慧榮,趙琛,等.隔藥灸治療大鼠潰瘍性結(jié)腸炎差異表達(dá)基因研究[J].中國(guó)針灸,2005,25(5):359- 365.

[90] 馬鐵明,韓洋,馬賢德,等.不同灸量對(duì)潰瘍性結(jié)腸炎大鼠結(jié)腸上皮形態(tài)學(xué)及血清中炎性細(xì)胞因子、結(jié)腸組織中炎性細(xì)胞信號(hào)轉(zhuǎn)導(dǎo)通路的影響[J].針刺研究,2014, 39(1):20-26.

[91] 楊玲,吳璐一,竇傳字,等.隔藥灸對(duì)潰瘍性結(jié)腸炎大鼠結(jié)腸黏膜MyD88及TRAF6表達(dá)的影響[J].中華中醫(yī)藥學(xué)刊,2013,31(9):1864-1866,2080-2081.

[92] 李曉娟.溫和灸對(duì)小鼠細(xì)菌感染炎癥的影響及其自噬機(jī)制研究[D].湖北中醫(yī)藥大學(xué),2014.

Research Advances in the Relationship Between NLRP3 Inflammasome and Inflammatory Bowel Disease and the Regulating Effect of Acupuncture and Moxibustion

1,1,2,1,2,1,2,2,1,2.

1.201203,; 2.200030,

Inflammatory bowel disease (IBD) is a group of chronic nonspecific inflammatory intestinal diseases including Crohn's disease (CD) and ulcerative colitis (UC). The inflammasome is macromolecular multiprotein and plays an important role in inflammatory occurrence and development and bodily innate immunity. NLRP3 inflammasome produces a bidirectional regulating effect in the occurrence and development of IBD and the mechanism of maintaining intestinal homeostasis. This article reviews research advances in NLRP3 inflammasome in IBD, and the regulating effect of acupuncture and moxibustion on it and the possible mechanism to provide a new idea for clinical and mechanism studies of acupuncture-moxibustion treatment for inflammatory bowel disease.

Inflammatory bowel disease; Acupuncture-moxibustion therapy; Inflammasome; NLRP3

1005-0957(2018)08-0961-08

R2-03

A

10.13460/j.issn.1005-0957.2018.08.0961

2018-03-20

國(guó)家自然科學(xué)基金項(xiàng)目(81674073,81273843);國(guó)家重點(diǎn)基礎(chǔ)研究發(fā)展計(jì)劃項(xiàng)目(2015CB554501);上海市衛(wèi)生和計(jì)劃生育委員會(huì)項(xiàng)目(2017BR047)

吳麗潔(1990—),女,2017級(jí)博士生,Email:wljzwb@163.com

馬曉芃(1973—),女,研究員,博士生導(dǎo)師,Email:pengpengma@163.com